Fintel reports that on November 13, 2025, Benchmark maintained coverage of Humacyte (NasdaqGS:HUMA) with a Buy recommendation.
Analyst Price Forecast Suggests 622.45% Upside
As of November 9, 2025, the average one-year price target for Humacyte is $8.60/share. The forecasts range from a low of $3.03 to a high of $26.25. The average price target represents an increase of 622.45% from its latest reported closing price of $1.19 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Humacyte is 85MM, an increase of 5,288.73%. The projected annual non-GAAP EPS is -0.04.
What is the Fund Sentiment?
There are 268 funds or institutions reporting positions in Humacyte. This is an decrease of 18 owner(s) or 6.29% in the last quarter. Average portfolio weight of all funds dedicated to HUMA is 0.02%, an increase of 33.08%. Total shares owned by institutions decreased in the last three months by 19.87% to 58,992K shares. 
The put/call ratio of HUMA is 0.19, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,809K shares representing 2.03% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 3,104K shares representing 1.66% ownership of the company. In its prior filing, the firm reported owning 2,374K shares , representing an increase of 23.52%. The firm increased its portfolio allocation in HUMA by 61.81% over the last quarter.
Geode Capital Management holds 3,096K shares representing 1.65% ownership of the company. In its prior filing, the firm reported owning 2,949K shares , representing an increase of 4.77%. The firm decreased its portfolio allocation in HUMA by 57.73% over the last quarter.
Millennium Management holds 2,553K shares representing 1.36% ownership of the company. In its prior filing, the firm reported owning 1,340K shares , representing an increase of 47.51%. The firm increased its portfolio allocation in HUMA by 111.88% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 2,265K shares representing 1.21% ownership of the company. In its prior filing, the firm reported owning 2,266K shares , representing a decrease of 0.04%. The firm increased its portfolio allocation in HUMA by 29.78% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
